nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS1—kidney cancer	0.335	0.636	CbGaD
Mesalazine—PTGS2—kidney cancer	0.192	0.364	CbGaD
Mesalazine—PPARG—nephron—kidney cancer	0.00476	0.258	CbGeAlD
Mesalazine—PPARG—Everolimus—Temsirolimus—kidney cancer	0.00289	1	CbGdCrCtD
Mesalazine—PTGS2—nephron—kidney cancer	0.00243	0.132	CbGeAlD
Mesalazine—CHUK—renal system—kidney cancer	0.00221	0.12	CbGeAlD
Mesalazine—IKBKB—cortex of kidney—kidney cancer	0.00141	0.0766	CbGeAlD
Mesalazine—IKBKB—gonad—kidney cancer	0.00135	0.073	CbGeAlD
Mesalazine—MPO—renal system—kidney cancer	0.00105	0.0571	CbGeAlD
Mesalazine—MPO—kidney—kidney cancer	0.00102	0.0552	CbGeAlD
Mesalazine—PPARG—renal system—kidney cancer	0.000935	0.0507	CbGeAlD
Mesalazine—PPARG—kidney—kidney cancer	0.000904	0.049	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS1—kidney cancer	0.000839	0.185	CrCbGaD
Mesalazine—Olsalazine—PTGS1—kidney cancer	0.000575	0.127	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS1—kidney cancer	0.000541	0.119	CrCbGaD
Mesalazine—Diflunisal—PTGS1—kidney cancer	0.000541	0.119	CrCbGaD
Mesalazine—PTGS1—renal system—kidney cancer	0.0005	0.0271	CbGeAlD
Mesalazine—PTGS1—kidney—kidney cancer	0.000483	0.0262	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—kidney cancer	0.00048	0.106	CrCbGaD
Mesalazine—PTGS2—renal system—kidney cancer	0.000478	0.0259	CbGeAlD
Mesalazine—PTGS2—kidney—kidney cancer	0.000462	0.025	CbGeAlD
Mesalazine—PTGS1—cardiac atrium—kidney cancer	0.000448	0.0243	CbGeAlD
Mesalazine—Olsalazine—PTGS2—kidney cancer	0.000329	0.0724	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—kidney cancer	0.000309	0.0681	CrCbGaD
Mesalazine—Diflunisal—PTGS2—kidney cancer	0.000309	0.0681	CrCbGaD
Mesalazine—Salicylic acid—PTGS1—kidney cancer	0.000301	0.0662	CrCbGaD
Mesalazine—Salicylic acid—PTGS2—kidney cancer	0.000172	0.0379	CrCbGaD
Mesalazine—Salicylic acid—ABCB1—kidney cancer	0.000146	0.0322	CrCbGaD
Mesalazine—Infection—Paclitaxel—kidney cancer	5.85e-05	0.000205	CcSEcCtD
Mesalazine—Flatulence—Capecitabine—kidney cancer	5.84e-05	0.000205	CcSEcCtD
Mesalazine—Dry skin—Doxorubicin—kidney cancer	5.81e-05	0.000204	CcSEcCtD
Mesalazine—Dysgeusia—Capecitabine—kidney cancer	5.8e-05	0.000203	CcSEcCtD
Mesalazine—Dizziness—Sunitinib—kidney cancer	5.8e-05	0.000203	CcSEcCtD
Mesalazine—Feeling abnormal—Gemcitabine—kidney cancer	5.8e-05	0.000203	CcSEcCtD
Mesalazine—Shock—Paclitaxel—kidney cancer	5.8e-05	0.000203	CcSEcCtD
Mesalazine—Vomiting—Sorafenib—kidney cancer	5.8e-05	0.000203	CcSEcCtD
Mesalazine—Orthostatic hypotension—Doxorubicin—kidney cancer	5.79e-05	0.000203	CcSEcCtD
Mesalazine—Abdominal pain upper—Doxorubicin—kidney cancer	5.79e-05	0.000203	CcSEcCtD
Mesalazine—Nervous system disorder—Paclitaxel—kidney cancer	5.78e-05	0.000202	CcSEcCtD
Mesalazine—Thrombocytopenia—Paclitaxel—kidney cancer	5.77e-05	0.000202	CcSEcCtD
Mesalazine—Tachycardia—Paclitaxel—kidney cancer	5.75e-05	0.000202	CcSEcCtD
Mesalazine—Rash—Sorafenib—kidney cancer	5.75e-05	0.000201	CcSEcCtD
Mesalazine—Dermatitis—Sorafenib—kidney cancer	5.74e-05	0.000201	CcSEcCtD
Mesalazine—Back pain—Capecitabine—kidney cancer	5.73e-05	0.000201	CcSEcCtD
Mesalazine—Breast disorder—Doxorubicin—kidney cancer	5.73e-05	0.000201	CcSEcCtD
Mesalazine—Skin disorder—Paclitaxel—kidney cancer	5.72e-05	0.000201	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	5.71e-05	0.0002	CcSEcCtD
Mesalazine—Headache—Sorafenib—kidney cancer	5.71e-05	0.0002	CcSEcCtD
Mesalazine—Muscle spasms—Capecitabine—kidney cancer	5.7e-05	0.0002	CcSEcCtD
Mesalazine—Hyperhidrosis—Paclitaxel—kidney cancer	5.7e-05	0.0002	CcSEcCtD
Mesalazine—Diarrhoea—Dactinomycin—kidney cancer	5.68e-05	0.000199	CcSEcCtD
Mesalazine—Nasopharyngitis—Doxorubicin—kidney cancer	5.67e-05	0.000199	CcSEcCtD
Mesalazine—Anorexia—Paclitaxel—kidney cancer	5.62e-05	0.000197	CcSEcCtD
Mesalazine—Gastritis—Doxorubicin—kidney cancer	5.61e-05	0.000197	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	5.59e-05	0.000196	CcSEcCtD
Mesalazine—Vision blurred—Capecitabine—kidney cancer	5.58e-05	0.000196	CcSEcCtD
Mesalazine—Vomiting—Sunitinib—kidney cancer	5.58e-05	0.000195	CcSEcCtD
Mesalazine—Body temperature increased—Gemcitabine—kidney cancer	5.56e-05	0.000195	CcSEcCtD
Mesalazine—Tremor—Capecitabine—kidney cancer	5.55e-05	0.000195	CcSEcCtD
Mesalazine—Rash—Sunitinib—kidney cancer	5.53e-05	0.000194	CcSEcCtD
Mesalazine—Dermatitis—Sunitinib—kidney cancer	5.52e-05	0.000194	CcSEcCtD
Mesalazine—Abdominal distension—Doxorubicin—kidney cancer	5.52e-05	0.000193	CcSEcCtD
Mesalazine—Hypotension—Paclitaxel—kidney cancer	5.51e-05	0.000193	CcSEcCtD
Mesalazine—Ill-defined disorder—Capecitabine—kidney cancer	5.5e-05	0.000193	CcSEcCtD
Mesalazine—Headache—Sunitinib—kidney cancer	5.49e-05	0.000193	CcSEcCtD
Mesalazine—Dysphagia—Doxorubicin—kidney cancer	5.48e-05	0.000192	CcSEcCtD
Mesalazine—Influenza—Doxorubicin—kidney cancer	5.48e-05	0.000192	CcSEcCtD
Mesalazine—Asthma—Doxorubicin—kidney cancer	5.48e-05	0.000192	CcSEcCtD
Mesalazine—Anaemia—Capecitabine—kidney cancer	5.48e-05	0.000192	CcSEcCtD
Mesalazine—Hypersensitivity—Vincristine—kidney cancer	5.47e-05	0.000192	CcSEcCtD
Mesalazine—Eosinophilia—Doxorubicin—kidney cancer	5.43e-05	0.00019	CcSEcCtD
Mesalazine—Nausea—Sorafenib—kidney cancer	5.41e-05	0.00019	CcSEcCtD
Mesalazine—Pancreatitis—Doxorubicin—kidney cancer	5.37e-05	0.000188	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.37e-05	0.000188	CcSEcCtD
Mesalazine—Malaise—Capecitabine—kidney cancer	5.34e-05	0.000187	CcSEcCtD
Mesalazine—Angina pectoris—Doxorubicin—kidney cancer	5.34e-05	0.000187	CcSEcCtD
Mesalazine—Insomnia—Paclitaxel—kidney cancer	5.33e-05	0.000187	CcSEcCtD
Mesalazine—Vertigo—Capecitabine—kidney cancer	5.32e-05	0.000187	CcSEcCtD
Mesalazine—Asthenia—Vincristine—kidney cancer	5.32e-05	0.000187	CcSEcCtD
Mesalazine—Syncope—Capecitabine—kidney cancer	5.31e-05	0.000186	CcSEcCtD
Mesalazine—Leukopenia—Capecitabine—kidney cancer	5.3e-05	0.000186	CcSEcCtD
Mesalazine—Paraesthesia—Paclitaxel—kidney cancer	5.29e-05	0.000185	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—kidney cancer	5.28e-05	0.000185	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—kidney cancer	5.27e-05	0.000185	CcSEcCtD
Mesalazine—Dyspnoea—Paclitaxel—kidney cancer	5.25e-05	0.000184	CcSEcCtD
Mesalazine—Somnolence—Paclitaxel—kidney cancer	5.24e-05	0.000184	CcSEcCtD
Mesalazine—Palpitations—Capecitabine—kidney cancer	5.24e-05	0.000183	CcSEcCtD
Mesalazine—Rash—Dactinomycin—kidney cancer	5.24e-05	0.000183	CcSEcCtD
Mesalazine—Nausea—Sunitinib—kidney cancer	5.21e-05	0.000183	CcSEcCtD
Mesalazine—Loss of consciousness—Capecitabine—kidney cancer	5.21e-05	0.000182	CcSEcCtD
Mesalazine—Pancytopenia—Doxorubicin—kidney cancer	5.21e-05	0.000182	CcSEcCtD
Mesalazine—Dyspepsia—Paclitaxel—kidney cancer	5.19e-05	0.000182	CcSEcCtD
Mesalazine—Cough—Capecitabine—kidney cancer	5.17e-05	0.000181	CcSEcCtD
Mesalazine—Neutropenia—Doxorubicin—kidney cancer	5.13e-05	0.00018	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—kidney cancer	5.13e-05	0.00018	CcSEcCtD
Mesalazine—Decreased appetite—Paclitaxel—kidney cancer	5.12e-05	0.000179	CcSEcCtD
Mesalazine—Hypertension—Capecitabine—kidney cancer	5.12e-05	0.000179	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Doxorubicin—kidney cancer	5.09e-05	0.000179	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Paclitaxel—kidney cancer	5.09e-05	0.000178	CcSEcCtD
Mesalazine—Fatigue—Paclitaxel—kidney cancer	5.08e-05	0.000178	CcSEcCtD
Mesalazine—Diarrhoea—Vincristine—kidney cancer	5.08e-05	0.000178	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—kidney cancer	5.06e-05	0.000177	CcSEcCtD
Mesalazine—Asthenia—Gemcitabine—kidney cancer	5.05e-05	0.000177	CcSEcCtD
Mesalazine—Chest pain—Capecitabine—kidney cancer	5.04e-05	0.000177	CcSEcCtD
Mesalazine—Arthralgia—Capecitabine—kidney cancer	5.04e-05	0.000177	CcSEcCtD
Mesalazine—Myalgia—Capecitabine—kidney cancer	5.04e-05	0.000177	CcSEcCtD
Mesalazine—Pain—Paclitaxel—kidney cancer	5.04e-05	0.000177	CcSEcCtD
Mesalazine—Constipation—Paclitaxel—kidney cancer	5.04e-05	0.000177	CcSEcCtD
Mesalazine—Anxiety—Capecitabine—kidney cancer	5.03e-05	0.000176	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	5.01e-05	0.000176	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—kidney cancer	5e-05	0.000175	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—kidney cancer	4.99e-05	0.000175	CcSEcCtD
Mesalazine—Discomfort—Capecitabine—kidney cancer	4.98e-05	0.000175	CcSEcCtD
Mesalazine—Pruritus—Gemcitabine—kidney cancer	4.98e-05	0.000174	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—kidney cancer	4.96e-05	0.000174	CcSEcCtD
Mesalazine—Dry mouth—Capecitabine—kidney cancer	4.93e-05	0.000173	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—kidney cancer	4.93e-05	0.000173	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—kidney cancer	4.92e-05	0.000172	CcSEcCtD
Mesalazine—Dizziness—Vincristine—kidney cancer	4.91e-05	0.000172	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—kidney cancer	4.89e-05	0.000171	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—kidney cancer	4.89e-05	0.000171	CcSEcCtD
Mesalazine—Confusional state—Capecitabine—kidney cancer	4.88e-05	0.000171	CcSEcCtD
Mesalazine—Feeling abnormal—Paclitaxel—kidney cancer	4.86e-05	0.00017	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	4.85e-05	0.00017	CcSEcCtD
Mesalazine—Oedema—Capecitabine—kidney cancer	4.84e-05	0.000169	CcSEcCtD
Mesalazine—Gastrointestinal pain—Paclitaxel—kidney cancer	4.82e-05	0.000169	CcSEcCtD
Mesalazine—Diarrhoea—Gemcitabine—kidney cancer	4.82e-05	0.000169	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—kidney cancer	4.8e-05	0.000168	CcSEcCtD
Mesalazine—Infection—Capecitabine—kidney cancer	4.8e-05	0.000168	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—kidney cancer	4.79e-05	0.000168	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—kidney cancer	4.76e-05	0.000167	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—kidney cancer	4.76e-05	0.000167	CcSEcCtD
Mesalazine—Shock—Capecitabine—kidney cancer	4.76e-05	0.000167	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—kidney cancer	4.75e-05	0.000166	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—kidney cancer	4.75e-05	0.000166	CcSEcCtD
Mesalazine—Nervous system disorder—Capecitabine—kidney cancer	4.74e-05	0.000166	CcSEcCtD
Mesalazine—Thrombocytopenia—Capecitabine—kidney cancer	4.73e-05	0.000166	CcSEcCtD
Mesalazine—Tachycardia—Capecitabine—kidney cancer	4.72e-05	0.000165	CcSEcCtD
Mesalazine—Vomiting—Vincristine—kidney cancer	4.72e-05	0.000165	CcSEcCtD
Mesalazine—Skin disorder—Capecitabine—kidney cancer	4.7e-05	0.000165	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—kidney cancer	4.69e-05	0.000164	CcSEcCtD
Mesalazine—Urticaria—Paclitaxel—kidney cancer	4.68e-05	0.000164	CcSEcCtD
Mesalazine—Rash—Vincristine—kidney cancer	4.68e-05	0.000164	CcSEcCtD
Mesalazine—Hyperhidrosis—Capecitabine—kidney cancer	4.67e-05	0.000164	CcSEcCtD
Mesalazine—Dermatitis—Vincristine—kidney cancer	4.67e-05	0.000164	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—kidney cancer	4.66e-05	0.000163	CcSEcCtD
Mesalazine—Abdominal pain—Paclitaxel—kidney cancer	4.66e-05	0.000163	CcSEcCtD
Mesalazine—Body temperature increased—Paclitaxel—kidney cancer	4.66e-05	0.000163	CcSEcCtD
Mesalazine—Headache—Vincristine—kidney cancer	4.65e-05	0.000163	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—kidney cancer	4.62e-05	0.000162	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—kidney cancer	4.61e-05	0.000162	CcSEcCtD
Mesalazine—Anorexia—Capecitabine—kidney cancer	4.61e-05	0.000162	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—kidney cancer	4.58e-05	0.000161	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—kidney cancer	4.56e-05	0.00016	CcSEcCtD
Mesalazine—Hypotension—Capecitabine—kidney cancer	4.52e-05	0.000158	CcSEcCtD
Mesalazine—Vomiting—Gemcitabine—kidney cancer	4.47e-05	0.000157	CcSEcCtD
Mesalazine—Rash—Gemcitabine—kidney cancer	4.44e-05	0.000155	CcSEcCtD
Mesalazine—Dermatitis—Gemcitabine—kidney cancer	4.43e-05	0.000155	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—kidney cancer	4.41e-05	0.000155	CcSEcCtD
Mesalazine—Headache—Gemcitabine—kidney cancer	4.41e-05	0.000154	CcSEcCtD
Mesalazine—Nausea—Vincristine—kidney cancer	4.41e-05	0.000154	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.41e-05	0.000154	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—kidney cancer	4.4e-05	0.000154	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—kidney cancer	4.39e-05	0.000154	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—kidney cancer	4.39e-05	0.000154	CcSEcCtD
Mesalazine—Insomnia—Capecitabine—kidney cancer	4.37e-05	0.000153	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—kidney cancer	4.35e-05	0.000153	CcSEcCtD
Mesalazine—Paraesthesia—Capecitabine—kidney cancer	4.34e-05	0.000152	CcSEcCtD
Mesalazine—Hypersensitivity—Paclitaxel—kidney cancer	4.34e-05	0.000152	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—kidney cancer	4.33e-05	0.000152	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—kidney cancer	4.32e-05	0.000151	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—kidney cancer	4.31e-05	0.000151	CcSEcCtD
Mesalazine—Dyspnoea—Capecitabine—kidney cancer	4.31e-05	0.000151	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—kidney cancer	4.3e-05	0.000151	CcSEcCtD
Mesalazine—Dyspepsia—Capecitabine—kidney cancer	4.26e-05	0.000149	CcSEcCtD
Mesalazine—Asthenia—Paclitaxel—kidney cancer	4.23e-05	0.000148	CcSEcCtD
Mesalazine—Decreased appetite—Capecitabine—kidney cancer	4.2e-05	0.000147	CcSEcCtD
Mesalazine—Nausea—Gemcitabine—kidney cancer	4.18e-05	0.000146	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Capecitabine—kidney cancer	4.17e-05	0.000146	CcSEcCtD
Mesalazine—Fatigue—Capecitabine—kidney cancer	4.17e-05	0.000146	CcSEcCtD
Mesalazine—Pruritus—Paclitaxel—kidney cancer	4.17e-05	0.000146	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—kidney cancer	4.15e-05	0.000145	CcSEcCtD
Mesalazine—Constipation—Capecitabine—kidney cancer	4.13e-05	0.000145	CcSEcCtD
Mesalazine—Pain—Capecitabine—kidney cancer	4.13e-05	0.000145	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—kidney cancer	4.1e-05	0.000144	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—kidney cancer	4.09e-05	0.000143	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—kidney cancer	4.07e-05	0.000143	CcSEcCtD
Mesalazine—Diarrhoea—Paclitaxel—kidney cancer	4.03e-05	0.000141	CcSEcCtD
Mesalazine—Feeling abnormal—Capecitabine—kidney cancer	3.98e-05	0.00014	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—kidney cancer	3.98e-05	0.000139	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—kidney cancer	3.96e-05	0.000139	CcSEcCtD
Mesalazine—Gastrointestinal pain—Capecitabine—kidney cancer	3.95e-05	0.000139	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—kidney cancer	3.95e-05	0.000139	CcSEcCtD
Mesalazine—Chills—Doxorubicin—kidney cancer	3.94e-05	0.000138	CcSEcCtD
Mesalazine—Dizziness—Paclitaxel—kidney cancer	3.9e-05	0.000137	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—kidney cancer	3.88e-05	0.000136	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—kidney cancer	3.84e-05	0.000135	CcSEcCtD
Mesalazine—Urticaria—Capecitabine—kidney cancer	3.84e-05	0.000135	CcSEcCtD
Mesalazine—Abdominal pain—Capecitabine—kidney cancer	3.82e-05	0.000134	CcSEcCtD
Mesalazine—Body temperature increased—Capecitabine—kidney cancer	3.82e-05	0.000134	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—kidney cancer	3.82e-05	0.000134	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—kidney cancer	3.76e-05	0.000132	CcSEcCtD
Mesalazine—Tension—Doxorubicin—kidney cancer	3.75e-05	0.000131	CcSEcCtD
Mesalazine—Vomiting—Paclitaxel—kidney cancer	3.75e-05	0.000131	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—kidney cancer	3.74e-05	0.000131	CcSEcCtD
Mesalazine—Rash—Paclitaxel—kidney cancer	3.72e-05	0.00013	CcSEcCtD
Mesalazine—Dermatitis—Paclitaxel—kidney cancer	3.71e-05	0.00013	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—kidney cancer	3.71e-05	0.00013	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—kidney cancer	3.69e-05	0.000129	CcSEcCtD
Mesalazine—Headache—Paclitaxel—kidney cancer	3.69e-05	0.000129	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—kidney cancer	3.67e-05	0.000129	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—kidney cancer	3.6e-05	0.000126	CcSEcCtD
Mesalazine—Hypersensitivity—Capecitabine—kidney cancer	3.56e-05	0.000125	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—kidney cancer	3.54e-05	0.000124	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—kidney cancer	3.53e-05	0.000124	CcSEcCtD
Mesalazine—Nausea—Paclitaxel—kidney cancer	3.5e-05	0.000123	CcSEcCtD
Mesalazine—Asthenia—Capecitabine—kidney cancer	3.47e-05	0.000122	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—kidney cancer	3.44e-05	0.000121	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—kidney cancer	3.43e-05	0.00012	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—kidney cancer	3.42e-05	0.00012	CcSEcCtD
Mesalazine—Pruritus—Capecitabine—kidney cancer	3.42e-05	0.00012	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—kidney cancer	3.42e-05	0.00012	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—kidney cancer	3.37e-05	0.000118	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—kidney cancer	3.36e-05	0.000118	CcSEcCtD
Mesalazine—Cough—Doxorubicin—kidney cancer	3.33e-05	0.000117	CcSEcCtD
Mesalazine—Diarrhoea—Capecitabine—kidney cancer	3.31e-05	0.000116	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—kidney cancer	3.3e-05	0.000116	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—kidney cancer	3.25e-05	0.000114	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—kidney cancer	3.25e-05	0.000114	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—kidney cancer	3.25e-05	0.000114	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—kidney cancer	3.24e-05	0.000114	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.23e-05	0.000113	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—kidney cancer	3.21e-05	0.000113	CcSEcCtD
Mesalazine—Dizziness—Capecitabine—kidney cancer	3.2e-05	0.000112	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—kidney cancer	3.18e-05	0.000111	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—kidney cancer	3.14e-05	0.00011	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—kidney cancer	3.12e-05	0.000109	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—kidney cancer	3.12e-05	0.000109	CcSEcCtD
Mesalazine—Infection—Doxorubicin—kidney cancer	3.1e-05	0.000109	CcSEcCtD
Mesalazine—Vomiting—Capecitabine—kidney cancer	3.07e-05	0.000108	CcSEcCtD
Mesalazine—Shock—Doxorubicin—kidney cancer	3.07e-05	0.000107	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—kidney cancer	3.06e-05	0.000107	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—kidney cancer	3.05e-05	0.000107	CcSEcCtD
Mesalazine—Rash—Capecitabine—kidney cancer	3.05e-05	0.000107	CcSEcCtD
Mesalazine—Dermatitis—Capecitabine—kidney cancer	3.05e-05	0.000107	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—kidney cancer	3.04e-05	0.000107	CcSEcCtD
Mesalazine—Headache—Capecitabine—kidney cancer	3.03e-05	0.000106	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—kidney cancer	3.03e-05	0.000106	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—kidney cancer	3.01e-05	0.000106	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—kidney cancer	2.97e-05	0.000104	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—kidney cancer	2.91e-05	0.000102	CcSEcCtD
Mesalazine—Nausea—Capecitabine—kidney cancer	2.87e-05	0.000101	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.84e-05	9.95e-05	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—kidney cancer	2.82e-05	9.88e-05	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—kidney cancer	2.8e-05	9.81e-05	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—kidney cancer	2.78e-05	9.74e-05	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—kidney cancer	2.77e-05	9.71e-05	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—kidney cancer	2.74e-05	9.61e-05	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—kidney cancer	2.71e-05	9.49e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.69e-05	9.43e-05	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—kidney cancer	2.69e-05	9.42e-05	CcSEcCtD
Mesalazine—Pain—Doxorubicin—kidney cancer	2.67e-05	9.34e-05	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—kidney cancer	2.67e-05	9.34e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—kidney cancer	2.57e-05	9e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—kidney cancer	2.55e-05	8.93e-05	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—kidney cancer	2.48e-05	8.68e-05	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—kidney cancer	2.46e-05	8.63e-05	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—kidney cancer	2.46e-05	8.63e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—kidney cancer	2.3e-05	8.05e-05	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—kidney cancer	2.24e-05	7.84e-05	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—kidney cancer	2.21e-05	7.73e-05	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—kidney cancer	2.13e-05	7.47e-05	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—kidney cancer	2.06e-05	7.22e-05	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—kidney cancer	1.98e-05	6.94e-05	CcSEcCtD
Mesalazine—Rash—Doxorubicin—kidney cancer	1.97e-05	6.89e-05	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—kidney cancer	1.96e-05	6.88e-05	CcSEcCtD
Mesalazine—Headache—Doxorubicin—kidney cancer	1.95e-05	6.84e-05	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—kidney cancer	1.85e-05	6.49e-05	CcSEcCtD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.76e-05	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN2B—kidney cancer	1.76e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	1.74e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—RAF1—kidney cancer	1.74e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—RELA—kidney cancer	1.73e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERBB2—kidney cancer	1.72e-05	0.000106	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PIK3CA—kidney cancer	1.71e-05	0.000106	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ITPR2—kidney cancer	1.7e-05	0.000105	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—POMC—kidney cancer	1.7e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—MTOR—kidney cancer	1.69e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD4—kidney cancer	1.69e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ANXA1—kidney cancer	1.68e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSMD7—kidney cancer	1.68e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TSC1—kidney cancer	1.68e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.68e-05	0.000104	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—kidney cancer	1.66e-05	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CDKN1B—kidney cancer	1.66e-05	0.000102	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.65e-05	0.000102	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNA1—kidney cancer	1.65e-05	0.000102	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EIF4EBP1—kidney cancer	1.64e-05	0.000102	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HSPB1—kidney cancer	1.64e-05	0.000102	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.64e-05	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—RAF1—kidney cancer	1.64e-05	0.000101	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ACHE—kidney cancer	1.64e-05	0.000101	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTT1—kidney cancer	1.64e-05	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FLT1—kidney cancer	1.63e-05	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—RELA—kidney cancer	1.63e-05	0.000101	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—kidney cancer	1.62e-05	0.0001	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB2—kidney cancer	1.62e-05	0.0001	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD8A—kidney cancer	1.62e-05	0.0001	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTP1—kidney cancer	1.62e-05	0.0001	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MTOR—kidney cancer	1.6e-05	9.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD4—kidney cancer	1.6e-05	9.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1B—kidney cancer	1.59e-05	9.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—JUN—kidney cancer	1.58e-05	9.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—RAF1—kidney cancer	1.57e-05	9.72e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK3—kidney cancer	1.57e-05	9.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—RELA—kidney cancer	1.57e-05	9.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CTNNB1—kidney cancer	1.56e-05	9.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB2—kidney cancer	1.56e-05	9.62e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SCARB1—kidney cancer	1.55e-05	9.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.54e-05	9.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—MTOR—kidney cancer	1.54e-05	9.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD4—kidney cancer	1.53e-05	9.47e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ABCB1—kidney cancer	1.53e-05	9.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CRABP1—kidney cancer	1.53e-05	9.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSMD7—kidney cancer	1.53e-05	9.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSC1—kidney cancer	1.53e-05	9.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ANXA1—kidney cancer	1.53e-05	9.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTEN—kidney cancer	1.52e-05	9.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TSC2—kidney cancer	1.52e-05	9.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUNB—kidney cancer	1.51e-05	9.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PAK1—kidney cancer	1.51e-05	9.34e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PSMD7—kidney cancer	1.5e-05	9.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1B—kidney cancer	1.5e-05	9.28e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK1—kidney cancer	1.49e-05	9.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.49e-05	9.22e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTM1—kidney cancer	1.49e-05	9.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FLT1—kidney cancer	1.48e-05	9.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—kidney cancer	1.46e-05	9.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1B—kidney cancer	1.44e-05	8.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—JUN—kidney cancer	1.43e-05	8.83e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—BCHE—kidney cancer	1.42e-05	8.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSMD7—kidney cancer	1.42e-05	8.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ITPR2—kidney cancer	1.42e-05	8.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—kidney cancer	1.42e-05	8.76e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—kidney cancer	1.41e-05	8.72e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP1A1—kidney cancer	1.41e-05	8.71e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC5A5—kidney cancer	1.41e-05	8.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HIF1A—kidney cancer	1.41e-05	8.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TSC2—kidney cancer	1.4e-05	8.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—kidney cancer	1.38e-05	8.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TSC2—kidney cancer	1.38e-05	8.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUNB—kidney cancer	1.37e-05	8.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PAK1—kidney cancer	1.37e-05	8.47e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC2A1—kidney cancer	1.36e-05	8.4e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—kidney cancer	1.35e-05	8.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIT—kidney cancer	1.34e-05	8.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—kidney cancer	1.33e-05	8.2e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.32e-05	8.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.31e-05	8.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK3—kidney cancer	1.3e-05	8.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTT1—kidney cancer	1.3e-05	8.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ACHE—kidney cancer	1.3e-05	8.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A1—kidney cancer	1.29e-05	7.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—JUNB—kidney cancer	1.28e-05	7.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK1—kidney cancer	1.24e-05	7.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APC—kidney cancer	1.24e-05	7.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KIT—kidney cancer	1.24e-05	7.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF2—kidney cancer	1.24e-05	7.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—kidney cancer	1.23e-05	7.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN2B—kidney cancer	1.23e-05	7.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SCARB1—kidney cancer	1.23e-05	7.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTGS1—kidney cancer	1.22e-05	7.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIT—kidney cancer	1.22e-05	7.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1R—kidney cancer	1.2e-05	7.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSMD7—kidney cancer	1.19e-05	7.37e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—kidney cancer	1.18e-05	7.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK3—kidney cancer	1.18e-05	7.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—kidney cancer	1.17e-05	7.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—kidney cancer	1.16e-05	7.19e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.16e-05	7.16e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.15e-05	7.11e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—kidney cancer	1.13e-05	7.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—BCHE—kidney cancer	1.13e-05	6.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—kidney cancer	1.12e-05	6.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK1—kidney cancer	1.12e-05	6.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF2—kidney cancer	1.12e-05	6.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—kidney cancer	1.12e-05	6.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC5A5—kidney cancer	1.12e-05	6.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN2B—kidney cancer	1.12e-05	6.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1R—kidney cancer	1.08e-05	6.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A1—kidney cancer	1.08e-05	6.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—kidney cancer	1.08e-05	6.64e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCB1—kidney cancer	1.07e-05	6.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—kidney cancer	1.06e-05	6.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RAF1—kidney cancer	1.05e-05	6.5e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—kidney cancer	1.05e-05	6.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RELA—kidney cancer	1.05e-05	6.47e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—kidney cancer	1.04e-05	6.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN2B—kidney cancer	1.04e-05	6.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—kidney cancer	1.04e-05	6.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—kidney cancer	1.03e-05	6.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MTOR—kidney cancer	1.03e-05	6.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—kidney cancer	1.03e-05	6.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—kidney cancer	1.02e-05	6.3e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1A1—kidney cancer	9.88e-06	6.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—kidney cancer	9.84e-06	6.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TSC2—kidney cancer	9.82e-06	6.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—kidney cancer	9.75e-06	6.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RAF1—kidney cancer	9.72e-06	6e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—kidney cancer	9.64e-06	5.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—kidney cancer	9.61e-06	5.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAF1—kidney cancer	9.54e-06	5.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RELA—kidney cancer	9.5e-06	5.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—kidney cancer	9.49e-06	5.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—kidney cancer	9.47e-06	5.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—kidney cancer	9.44e-06	5.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—kidney cancer	9.44e-06	5.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—kidney cancer	9.41e-06	5.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—kidney cancer	9.4e-06	5.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—kidney cancer	9.36e-06	5.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—kidney cancer	9.32e-06	5.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—kidney cancer	9.3e-06	5.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—kidney cancer	9.18e-06	5.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.13e-06	5.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—kidney cancer	9.11e-06	5.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—kidney cancer	9e-06	5.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—kidney cancer	8.92e-06	5.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—kidney cancer	8.9e-06	5.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSC2—kidney cancer	8.9e-06	5.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—kidney cancer	8.88e-06	5.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—kidney cancer	8.74e-06	5.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—kidney cancer	8.67e-06	5.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—kidney cancer	8.67e-06	5.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—kidney cancer	8.56e-06	5.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—kidney cancer	8.53e-06	5.27e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—kidney cancer	8.52e-06	5.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—kidney cancer	8.41e-06	5.2e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—kidney cancer	8.38e-06	5.18e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—kidney cancer	8.33e-06	5.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—kidney cancer	8.32e-06	5.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—kidney cancer	8.32e-06	5.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TSC2—kidney cancer	8.3e-06	5.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—kidney cancer	8.27e-06	5.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—kidney cancer	8.26e-06	5.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—kidney cancer	8.25e-06	5.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—kidney cancer	8.2e-06	5.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—kidney cancer	8.15e-06	5.04e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.11e-06	5.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—kidney cancer	8.05e-06	4.97e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—kidney cancer	8.04e-06	4.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—kidney cancer	7.86e-06	4.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—kidney cancer	7.86e-06	4.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A1—kidney cancer	7.84e-06	4.84e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—kidney cancer	7.82e-06	4.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—kidney cancer	7.59e-06	4.69e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—kidney cancer	7.48e-06	4.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—kidney cancer	7.39e-06	4.57e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—kidney cancer	7.36e-06	4.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—kidney cancer	7.33e-06	4.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—kidney cancer	7.33e-06	4.53e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—kidney cancer	7.31e-06	4.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—kidney cancer	7.22e-06	4.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—kidney cancer	7e-06	4.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—kidney cancer	6.89e-06	4.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—kidney cancer	6.88e-06	4.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—kidney cancer	6.82e-06	4.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—kidney cancer	6.81e-06	4.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAF1—kidney cancer	6.8e-06	4.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RELA—kidney cancer	6.77e-06	4.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—kidney cancer	6.73e-06	4.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—kidney cancer	6.66e-06	4.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—kidney cancer	6.64e-06	4.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—kidney cancer	6.55e-06	4.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.44e-06	3.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—kidney cancer	6.29e-06	3.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—kidney cancer	6.26e-06	3.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—kidney cancer	6.23e-06	3.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—kidney cancer	6.18e-06	3.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAF1—kidney cancer	6.17e-06	3.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RELA—kidney cancer	6.14e-06	3.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—kidney cancer	6.1e-06	3.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—kidney cancer	6.1e-06	3.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—kidney cancer	6.02e-06	3.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—kidney cancer	5.95e-06	3.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—kidney cancer	5.93e-06	3.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—kidney cancer	5.89e-06	3.64e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—kidney cancer	5.87e-06	3.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—kidney cancer	5.85e-06	3.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—kidney cancer	5.78e-06	3.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAF1—kidney cancer	5.76e-06	3.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—kidney cancer	5.74e-06	3.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—kidney cancer	5.69e-06	3.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—kidney cancer	5.68e-06	3.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—kidney cancer	5.65e-06	3.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—kidney cancer	5.62e-06	3.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—kidney cancer	5.61e-06	3.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—kidney cancer	5.53e-06	3.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—kidney cancer	5.39e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—kidney cancer	5.38e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—kidney cancer	5.34e-06	3.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—kidney cancer	5.27e-06	3.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—kidney cancer	5.2e-06	3.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—kidney cancer	5.18e-06	3.2e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—kidney cancer	5.16e-06	3.19e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—kidney cancer	5.12e-06	3.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—kidney cancer	4.98e-06	3.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—kidney cancer	4.9e-06	3.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—kidney cancer	4.86e-06	3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—kidney cancer	4.77e-06	2.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—kidney cancer	4.7e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—kidney cancer	4.67e-06	2.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—kidney cancer	4.45e-06	2.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—kidney cancer	4.41e-06	2.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—kidney cancer	4.33e-06	2.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—kidney cancer	4.23e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—kidney cancer	4.15e-06	2.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—kidney cancer	4.07e-06	2.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—kidney cancer	4.05e-06	2.5e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—kidney cancer	4.04e-06	2.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—kidney cancer	4e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—kidney cancer	3.95e-06	2.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—kidney cancer	3.92e-06	2.42e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—kidney cancer	3.73e-06	2.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—kidney cancer	3.67e-06	2.27e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—kidney cancer	3.61e-06	2.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—kidney cancer	3.55e-06	2.2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—kidney cancer	3.43e-06	2.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—kidney cancer	2.87e-06	1.77e-05	CbGpPWpGaD
